For instance, the use of the Imatinib drug that targets the BCR-abl fusion protein in patients with chronic myelogenous leukemia (CML) first seemed to be one of the most successful targeted therapies. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.